Journal of Thrombosis and Thrombolysis

, Volume 38, Issue 2, pp 241–249

Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis

  • Minh Phan
  • Sonia John
  • Ana I. Casanegra
  • Suman Rathbun
  • Aaron Mansfield
  • Julie A. Stoner
  • Alfonso J. Tafur


Venous thromboembolism (VTE) is a leading cause of death among outpatient chemotherapy patients. However the VTE preventive measures for outpatients are not widely advocated. We did a meta-analysis to evaluate the outpatient VTE prevention’s effectiveness and safety. We searched electronic databases until the end of December 2012 and reviewed the abstracts and manuscripts following the PRISMA guidelines. Occurrence of first VTE event was the efficacy outcome. The safety end point was major bleeding. We calculated Q statistic and a homogeneity formal test. The odds ratio (OR) estimates were pooled by using the Mantel–Haenszel fixed-effects method in the absence of heterogeneity. Data were analyzed using the R META package). We identified 1,485 articles and reviewed 37 articles based on initial screening. The number of patients included in 11 selected trials was 7,805. The odds of VTE was lower in the prophylaxis group (OR 0.56; 95 % CI 0.45–0.71) and improved when heparin-based prevention was analyzed (OR 0.53; 95 % CI 0.41–0.70). We found strong prevention among patients with lung cancer (OR 0.46; 95 % CI 0.29–0.74) and pancreatic cancer (OR 0.33; 95 % CI 0.16–0.67). Major bleeding events were frequent in the intervention group (OR 1.65; 95 % CI 1.12–2.44). Thromboprophylaxis reduced VTE episodes. The VTE events were reduced by 47 % in heparin-based prophylaxis trials compared to placebo. The patients receiving heparin-based prophylaxis had a 60 % increase in bleeding events. Improving risk stratification tools to personalize prevention strategies may enhance the VTE prevention applicability in cancer patients.


Cancer Thromboembolism Prevention 


  1. 1.
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Int Med 160(6):809–815CrossRefGoogle Scholar
  2. 2.
    Roger VL et al (2012) Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125(1):e2–e220PubMedCrossRefGoogle Scholar
  3. 3.
    Khorana AA, Francis CW, Culakova E, Kudere NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632–634PubMedCrossRefGoogle Scholar
  4. 4.
    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846–1850PubMedCrossRefGoogle Scholar
  5. 5.
    Dobesh PP (2009) Economic Burden of Venous Thromboembolism in Hospitalized Patients. Pharmacotherapy 29(8):943–953PubMedCrossRefGoogle Scholar
  6. 6.
    Agnelli G et al (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366(7):601–609PubMedCrossRefGoogle Scholar
  7. 7.
    Heit JA et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809–815PubMedCrossRefGoogle Scholar
  8. 8.
    Heit JA et al (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160(6):761–768PubMedCrossRefGoogle Scholar
  9. 9.
    Streiff M et al (2013) Venous thromboembolic disease. National Comprenesive Cancer Network, WashingtonGoogle Scholar
  10. 10.
    Lyman GH et al (2007) American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505PubMedCrossRefGoogle Scholar
  11. 11.
    Mandala M, Falanga A, Roila F (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 22(6):vi85–vi92PubMedGoogle Scholar
  12. 12.
    Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H (2012) Schulman prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2):e195S–e226SPubMedCentralPubMedGoogle Scholar
  13. 13.
    Khorana AA et al (2012) Preventing VTE in outpatients with cancer. Chest 142(1):266–267CrossRefGoogle Scholar
  14. 14.
    Liberati A et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 (2006). Accessed Sept 1-27-2012
  16. 16.
    Egger M (2001) Systematic reviews in health care. In: Altman D (ed) Meta-analysis in Contex. BMJ Books, LondonGoogle Scholar
  17. 17.
    Huedo-Medina TB et al (2006) Assessing heterogeneity in meta-analysis: q statistic or I2 index? Psychol Methods 11(2):193–206PubMedCrossRefGoogle Scholar
  18. 18.
    Higgins JP et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMedGoogle Scholar
  20. 20.
    Young AM et al (2009) Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 373(9663):567–574PubMedCrossRefGoogle Scholar
  21. 21.
    Haas SK et al (2012) Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 18(2):159–165PubMedCrossRefGoogle Scholar
  22. 22.
    Levine M et al (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343(8902):886–889PubMedCrossRefGoogle Scholar
  23. 23.
    Kakkar AK et al (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22(10):1944–1948PubMedCrossRefGoogle Scholar
  24. 24.
    Perry JR et al (2010) PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 8(9):1959–1965PubMedCrossRefGoogle Scholar
  25. 25.
    Maraveyas A et al (2012) Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 48(9):1283–1292PubMedCrossRefGoogle Scholar
  26. 26.
    Klerk CPW et al (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23(10):2130–2135PubMedCrossRefGoogle Scholar
  27. 27.
    van Doormaal FF et al (2011) Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 29(15):2071–2076PubMedCrossRefGoogle Scholar
  28. 28.
    Agnelli G et al (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology 10(10):943–949PubMedCrossRefGoogle Scholar
  29. 29.
    Di Nisio M et al (2012) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 15(2):CD008500Google Scholar
  30. 30.
    Altinbas M et al (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2(8):1266–1271PubMedCrossRefGoogle Scholar
  31. 31.
    Sideras K et al (2006) Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 81(6):758–767PubMedCrossRefGoogle Scholar
  32. 32.
    Akl EA et al (2011) Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 15(6):CD006650Google Scholar
  33. 33.
    Verso M, Gussoni G, Agnelli G (2010) Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost 8(7):1649–1651PubMedCrossRefGoogle Scholar
  34. 34.
    Pishko AM, Smith KJ, Ragni MV (2012) Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective. Thromb Haemost 108(2):303–310PubMedCrossRefGoogle Scholar
  35. 35.
    Carrier M et al (2012) Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. J Thromb Haemost 10(12):2599–2601PubMedCrossRefGoogle Scholar
  36. 36.
    Debourdeau P et al (2013) International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 11(1):71–80PubMedCrossRefGoogle Scholar
  37. 37.
    Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21(19):3665–3675PubMedCrossRefGoogle Scholar
  38. 38.
    Lee AY et al (2006) Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 24(9):1404–1408PubMedCrossRefGoogle Scholar
  39. 39.
    Evans RS et al (2010) Risk of symptomatic DVT associated with peripherally inserted central catheters. Chest 138(4):803–810PubMedCrossRefGoogle Scholar
  40. 40.
    Levine MN et al (2012) A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 10(5):807–814PubMedCrossRefGoogle Scholar
  41. 41.
    Verso M et al (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the protecht score. Intern Emerg Med 7(3):291–292PubMedCrossRefGoogle Scholar
  42. 42.
    Barni S et al (2011) Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 9:179PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Ay C et al (2008) High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112(7):2703–2708PubMedCrossRefGoogle Scholar
  44. 44.
    Khorana AA et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Connolly GC et al (2010) Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 126(2):113–118PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Date K et al (2013) Tumour and microparticle tissue factor expression and cancer thrombosis. Thromb Res 131(2):109–115PubMedCrossRefGoogle Scholar
  47. 47.
    Zwicker JI et al (2013) Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol 160(4):530–537PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Stender MT et al (2009) Preoperative plasma D-dimer is a predictor of postoperative deep venous thrombosis in colorectal cancer patients: a clinical, prospective cohort study with one-year follow-up. Dis Colon Rectum 52(3):446–451PubMedCrossRefGoogle Scholar
  49. 49.
    Zwicker JI et al (2009) Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15(22):6830–6840PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Minh Phan
    • 1
  • Sonia John
    • 1
  • Ana I. Casanegra
    • 2
  • Suman Rathbun
    • 2
  • Aaron Mansfield
    • 3
  • Julie A. Stoner
    • 4
  • Alfonso J. Tafur
    • 2
  1. 1.Internal MedicineUniversity of Oklahoma Health Sciences CenterOklahoma CityUSA
  2. 2.Cardiovascular Medicine SectionUniversity of Oklahoma Health Sciences CenterOklahoma CityUSA
  3. 3.Department of Medical OncologyMayo ClinicRochesterUSA
  4. 4.Department of Biostatistics and EpidemiologyUniversity of Oklahoma Health and Sciences CenterOklahoma CityUSA

Personalised recommendations